Pneumagen: against COVID-19 ^Company

Entity: Pneumagen

Category: Treatment Development

Description: Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.

Project: Drug candidates in Pneumagen's GlycoTarge platform for prevention and treatment; Neumifil

Summary: University of St Andrews spin-out Pneumagen has reported positive findings from three in-vitro studies of Neumifil and other multivalent carbohydrate binding modules (mCBMs) to prevent infection by coronaviruses, including SARS-CoV-2. The drug candidates are based on the company’s GlycoTarge platform, which can be used to create glycan targeted mCBMs from bacterial glycosidases. These mCBMs could help prevent and also treat respiratory tract infections (RTIs) via attachment to epithelial cell surface glycan receptors in the respiratory tract, said Pneumagen. Neumifil is the company’s lead candidate already being developed as a universal therapy for respiratory tract infections (RTIs), including influenza virus (IFV) and respiratory syncytial virus (RSV).

+ Investors:

Scottish Investment Bank
Thairm Bio